The award-winning series explores the future of scientific communications, how digital tools can empower patients and why OutDoing Cancer is a team sport.
Listen to the new season now.
The future of America’s biomedical prowess hangs in the balance as far-reaching funding cuts tear through the scientific community.
In the span of just a few months, the Trump administration clawed back more than $2 billion in research grants from NIH, according to an analysis this week from Stat News. The cuts, which hit scores of colleges large and small, have accompanied signs that China’s biotechnology dominance is growing while America’s is shrinking. Just one institution in the U.S. — Harvard University — was among Nature’s top 10 research leaders in 2024, while seven were in China.
And the NIH reductions are far from over. Today, we’re looking at the programs impacted by grant terminations and at the Trump’s administration’s proposed vision for a newly organized — and much smaller — NIH.
A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.
Cell therapy technology has become a shining star in oncology, with CAR-T cell therapies transforming standards of care in blood cancers like lymphoma. Explore recent progress in this Trendline.
PharmaVoice readers who aren’t sure if the industry is ready to stop animal testing. Another 38% said pharma is not ready for the practice to end, and just 20% said it is.
Real-world evidence (RWE) offers a low-risk, high-reward means to increase efficiency and accelerate clinical trial timelines. Explore key use cases for RWD in life sciences innovations in this webinar.
